Voriconazole Test System Classified as Class II by FDA
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting the voriconazole test system into a special safety category called Class II, which means it has extra rules to keep it safe and effective. This change helps patients get access to this important medical test faster and with fewer red tapes. If you make or use these tests, get ready for new rules that kick in soon but won’t break the bank.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Patients May Get Faster Test Access
You may get faster access to the voriconazole test because the FDA has classified the voriconazole test system as Class II (special controls). The FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access to beneficial innovative devices by reducing regulatory burdens.
Manufacturers Subject to Class II Controls
If you make the voriconazole test system, the FDA has placed the device into Class II (special controls) and the special controls will be codified in the device's classification. The FDA says this classification provides a reasonable assurance of safety and effectiveness and that it will reduce regulatory burdens for such devices.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-08147 — Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Breast Milk Macronutrients Test System
The FDA is officially putting breast milk macronutrient test systems into a special safety group called Class II. This means these devices will have clear rules to keep them safe and effective, helping moms and babies get better access to these helpful tools faster. This change cuts red tape without adding extra costs, making it easier for companies to bring these devices to market.
Next: 2025-08149 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect Nucleic Acids From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections and Associated Resistance Marker(s)
The FDA is officially classifying a new device that detects germs causing sexually transmitted infections and their resistance markers as a Class II device with special safety rules. This change helps make sure the device is safe and works well, while also making it easier for patients to get access to these important tests. Companies making these devices will follow new guidelines starting now, which could speed up innovation without extra costs.